Chimeric Therapeutics因其针对胃癌的CDH17细胞疗法获得FDA孤儿药资格，并享有激励和独家性。 Chimeric Therapeutics gets FDA orphan drug status for its CDH17 cell therapy targeting gastric cancer, with incentives and exclusivity.

Chimeric治疗机构因针对胃癌的CHM CDH17细胞治疗而获得美国药管局孤儿药品指认,提供税收抵免和潜在的7年市场排他性等奖励。 Chimeric Therapeutics has received FDA Orphan Drug Designation for its CHM CDH17 cell therapy targeting gastric cancer, offering incentives like tax credits and potential seven-year market exclusivity. 该疗法针对固态肿瘤中的CDH17蛋白质,目前正在第1/2阶段试验中进行测试,涉及结肠和胃癌晚期患者,迄今已有9名患者接受治疗。 The therapy, which targets the CDH17 protein in solid tumors, is being tested in a Phase 1/2 trial involving patients with advanced colorectal and gastric cancers, with nine patients treated so far. FDA的命名反映了胃癌的罕见疾病状况,影响到美国不到200 000人。 The FDA’s designation reflects the rare disease status of gastric cancer, affecting fewer than 200,000 people in the U.S. 该公司继续推进其用于固态肿瘤的创新细胞疗法的管道。 The company continues advancing its pipeline of innovative cell therapies for solid tumors.